GlassScriptPhysician profile
Michael Thomas Massengill
NPI 1780213025
$2,410.56
in general payments reported to CMS, 2019-2025
7 companies · $993 in 2025
The $993 reported for 2025 was more than what 77% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,418 · 2025: $993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,556 · Travel and Lodging: $855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,555.85 |
| Travel and Lodging | $854.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,364.09 | 2024-2025 | Unity, Constellation |
| Bausch & Lomb Americas INC. | $388.67 | 2024-2025 | Miebo, Xiidra, Stellaris |
| Abbvie INC. | $237.00 | 2025 | |
| Astellas Pharma US INC | $158.71 | 2024 | Izervay |
| Dutch Ophthalmic, USA | $127.54 | 2025 | Eva, Combined Machine, Tissueblue |
| Regeneron Pharmaceuticals, INC. | $68.79 | 2025 | Eylea Hd |
| Apellis Pharmaceuticals, INC. | $65.76 | 2025 | Syfovre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Massengill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.